Relmada Therapeutics is a clinical-stage biotech developing differentiated therapies in oncology and CNS disorders. Its lead program, NDV-01, is a sustained-release intravesical combination of gemcitabine and docetaxel designed for non-muscle invasive bladder cancer, aiming for prolonged local drug exposure with simplified administration. A second candidate, sepranolone, modulates GABA-A receptor activity and is being advanced for compulsive behaviors, including Prader-Willi syndrome.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -9.9 | — |
| Q3 2025 | 0 | — | -10.1 | — |
| Q4 2025 | 0 | — | -19.9 | — |
| Q1 2026 | 0 | — | -19.1 | — |
| Q2 2026 | 0 | — | -12.9 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Clean Energy Fuels Corp. (CLNE), Oxley Bridge Acquisition Limited (OBA), Fifth Era Acquisition Corp I (FERA), Roman DBDR Acquisition Corp. II (DRDB), ProCap Acquisition Corp (PCAP), ASP Isotopes Inc. (ASPI)